US › Healthcare

Prelude Therapeutics Inc (PRLD)

US · Healthcare · Biotechnology

$4.57+2.24%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$5.7M

Net profit

$-13.9M

EPS

$-0.14

EPS estimate

$-0.17

Net margin

-244.1%

EPS came in at -0.14 against a street estimate of -0.17 — a beat of 17.6%.

Key statistics

Market cap

$372.7M

Forward P/E

0.0

P/B

3.03

Book value

$1.30

EPS (TTM)

$-0.67

52-week high

$6.83

52-week low

$0.98

50-day MA

$5.07

200-day MA

$3.65

Beta

0.96

Analyst view

Analysts rate Prelude Therapeutics Inc a buy (3 buy, 0 hold, 1 sell out of 4) with an average price target of $8.00.

Shareholding

Insiders

13.76%

Institutions

76.46%

Largest institutional holders

Fund	Stake
Orbimed Advisors LLC	13.67%
Baker Bros Advisors LP	12.69%
Soleus Capital Management, L.P.	4.23%
Kynam Capital Management, LP	3.03%
Vanguard Capital Management, LLC	1.54%
Two Sigma Investments LLC	1.16%
Millennium Management LLC	1.06%
Adage Capital Partners Gp LLC	0.96%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Prelude Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.